Previous 10 | Next 10 |
2024-04-26 13:25:32 ET AbbVie Inc. (ABBV) Q1 2024 Earnings Conference Call April 26, 2024 09:00 AM ET Company Participants Liz Shea - Vice President of Investor Relations Rick Gonzalez - Chairman of the Board & Chief Executive Officer Rob Michael - President ...
2024-04-26 12:01:50 ET Summary AbbVie's Q1 earnings beat estimates, with a smaller decline in Humira sales than expected. The company's next-generation drugs, Rinvoq and Skyrizi, are offsetting the decline in Humira sales. AbbVie's profitability will be weaker than in previous...
2024-04-26 11:20:12 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie off 3% despite quarterly beats, 2024 gu...
2024-04-26 10:33:56 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie Non-GAAP EPS of $2.31 beats by $0.05, r...
2024-04-26 09:10:34 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie Non-GAAP EPS of $2.31 beats by $0.05, r...
2024-04-26 09:08:00 ET U.S. stock index futures on Friday pointed to a rebound from the previous session, helped by a post-earnings advance in Microsoft ( MSFT ) and Alphabet ( GOOG ) ( GOOGL ). A key inflation reading also arrived in-line, helping sentiment. Here are some s...
2024-04-26 09:00:00 ET Summary Eaton Vance Enhanced Equity Income Fund is a closed-end fund that mainly invests in the equities of U.S. listed companies. The EOI CEF has a pretty strong long-term record of performance, even though it tends to underperform the S&P 500 slightly....
2024-04-26 08:17:26 ET Pharmaceuticals company AbbVie (NYSE: ABBV) reported its Q1 financial results for 2024 today. AbbVie’s earnings came in at $1.37 billion, or $0.77 per share, as compared with $239 million, or $0.13 per share, in Q1 of FY23. The company’s ...
2024-04-26 07:36:36 ET More on AbbVie AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment AbbVie: Through Humira's Crisis Towards Solid Growth AbbVie: Great To Be Proven Wrong - Still Not A Buy AbbVie reports positive results from Rinvoq ve...
AbbVie Reports First-Quarter 2024 Financial Results PR Newswire Reports First-Quarter Diluted EPS of $0.77 on a GAAP Basis, an Increase of 492.3 Percent; Adjusted Diluted EPS of $2.31 , a Decrease of 6.1 Percent; These Results Include an Unfavorable Impact of $0.08...
News, Short Squeeze, Breakout and More Instantly...
2024-05-20 10:58:01 ET Wall Street is feeling pretty good about AbbVie 's (NYSE: ABBV) performance in 2024 so far. Louise Chen from Cantor Fitzgerald recently initiated coverage on the stock with an overweight rating. Chen also slapped a $200 price target on the pharma stock, ...
President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA)...
Cantor Fitzgerald has initiated coverage on AbbVie Inc (NYSE:ABBV), a global pharma company. The analyst notes that the company has ...